And let's not forget the PD-L1 blockers which are slightly different in their action but accomplish the same thing, acting as a primer for those killer T cells to activate:

Atezolizumab (Tecentriq): Developed by Genentech, which is part of the Roche group.

Avelumab (Bavencio): Developed by Merck KGaA (the German Merck), often associated with collaborative efforts in its distribution.

Durvalumab (Imfinzi): Manufactured by AstraZeneca.

Which also brings 3 more European companies into the picture, which could be important.